Shopping Cart
Remove All
Your shopping cart is currently empty
BIW-8962 is a humanized anti-ganglioside GM2 antibody demonstrating ADCC/CDC activity against multiple myeloma cells. In murine xenograft models, BIW-8962 exhibits potent antitumor activity. This compound is applicable for research on cancers such as myeloma.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
| Description | BIW-8962 is a humanized anti-ganglioside GM2 antibody demonstrating ADCC/CDC activity against multiple myeloma cells. In murine xenograft models, BIW-8962 exhibits potent antitumor activity. This compound is applicable for research on cancers such as myeloma. |
| In vitro | BIW-8962 (0.01-1 μg/mL) exhibits ADCC activity in GM2-expressing SBC-3 cells. |
| In vivo | B BIW-8962 (0.1-10 mg/kg, administered intravenously every two weeks for 3-4 weeks) demonstrated anti-tumor activity in KMS-11 and OPM-2/GFP severe combined immunodeficiency (SCID) mouse models. In the SBC-3 SCID mouse model with natural killer cell depletion, BIW-8962 (0.1-10 μg/100μL, intravenously once daily on days 7, 14, 21, 28, and 35 post SBC-3 cell injection) effectively inhibited tumor metastasis across multiple organs, increased the number of apoptotic cells, and extended survival duration. |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.